0001522860FALSE00015228602024-11-142024-11-14

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_________________________________________
FORM 8-K
_________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 14, 2024
_________________________________________
Image_0.jpg
Acutus Medical, Inc.
(Exact name of Registrant as Specified in Its Charter)
_________________________________________
Delaware001-3943045-1306615
(State or Other Jurisdiction
of Incorporation)
(Commission File Number)
(IRS Employer
Identification No.)
2210 Faraday Ave., Suite 100
Carlsbad, CA
92008
(Address of Principal Executive Offices)(Zip Code)
Registrant’s Telephone Number, Including Area Code: (442) 232-6080
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
_________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of Each ClassTrading Symbol(s)Name of Each Exchange on Which Registered
Common Stock, par value $0.001AFIBN/A
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
1

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o


2


Item 2.02. Results of Operations and Financial Condition.

On November 14, 2024, the Company issued a press release announcing its financial results for the quarter ended September 30, 2024. A copy of this press release is attached as Exhibit 99.1 to this current report on Form 8-K.

The information under Item 2.02 in this current report on Form 8-K and the related information in the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”) or the Exchange Act, regardless of any general incorporation language in such filing.

Item 9.01.    Financial Statements and Exhibits.
(d)Exhibits
Exhibit
Number
Description
99.1
Press release dated November 14, 2024
104.0Cover Page Interactive Data File (embedded within the Inline XBRL document)



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Acutus Medical, Inc.
Date: November 14, 2024By:
/s/ Takeo Mukai
Takeo Mukai
Chief Executive Officer

3
Press ReleaseExhibit 99.1
image_1.jpg
Acutus Medical Reports Third Quarter and Year-To-Date 2024 Financial Results

CARLSBAD, Calif., November 14, 2024 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus” or the “Company”) (OTC: AFIB) today reported results for the third quarter and year-to-date of 2024.
Recent Highlights:

•Third quarter revenue from Continuing Operations of $5.3 million grew 156% year-over-year, from $2.1 million in the same quarter last year.

•Operating income for continuing operations was $0.1 million, an improvement of 119% compared to the same period last year.

•Recorded $2.4 million in gain on sale of business, a decrease of 8% compared to the same period last year.

•Cash, cash equivalents, marketable securities and restricted cash were $12.6 million as of September 30, 2024.

Third Quarter 2024 Financial Results
Revenue from Continuing Operations was $5.3 million for the third quarter of 2024, an increase of 156% compared to $2.1 million for the third quarter of 2023.

Gross margin on a GAAP basis for continuing operations was 7% for the third quarter of 2024 compared to negative 53% for the same quarter last year. The improvement was driven by higher production volumes related to left-heart access manufacturing and reduced manufacturing overhead expenses.

Operating income for continuing operations on a GAAP basis was $0.1 million for the third quarter of 2024 compared to Operating expenses of $0.6 million for the same period last year. The decrease in operating expenses from reduced discretionary spend under this new business model.

Net loss on continuing operations on a GAAP basis was $0.8 million for the third quarter of 2024 and net loss per share was $0.03 on a weighted average basic and diluted outstanding share count of 29.8 million, compared to a net loss of $1.9 million and a net loss per share of $0.7 on a weighted average basic and diluted outstanding share count of 29.3 million for the same period last year.

Cash, cash equivalents, marketable securities and restricted cash were $12.6 million as of September 30, 2024.

Loss on Discontinued Operations
Loss on discontinued operations was $4.8 million for third quarter of 2024, compared to $13.2 million for the same period last year.

Outlook
Due to the announced plan to realign resources to support the left-heart access distribution business and exit from the electrophysiology mapping and ablation businesses, the Company will no longer provide financial guidance.

About Acutus
Acutus is focused on the production of left-heart access products under its distribution agreement with Medtronic, Inc. Founded in 2011, Acutus is based in Carlsbad, California.

Caution Regarding Forward-Looking Statements
This press release includes statements that may constitute “forward-looking” statements, usually containing the words 'believe", "estimate", "project", "expect" or similar expressions. Forward looking statements inherently involve

    
image_1.jpg



risks and uncertainties that could cause actual results to differ materially from forward-looking statements.
Factors that would cause or contribute to such differences include, but are not limited to, the Company’s ability to continue to manage expenses and cash burn rate at sustainable levels, successful completion of the Company’s restructuring plan, continued acceptance of the Company’s left-heart access products in the marketplace, the effect of global economic conditions on the ability and willingness of Medtronic to purchase the Company’s left-heart access products and the timing of such purchases, competitive factors, changes resulting from healthcare policy in the United States and globally including changes in government reimbursement of procedures, dependence upon third-party vendors and distributors, timing of regulatory approvals, the Company’s ability to maintain its listing on Nasdaq, and other risks discussed in the Company’s periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, Acutus undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Investor Contact:
Chad Hollister
Acutus Medical, Inc.
investors@acutus.com


    
image_1.jpg
Acutus Medical, Inc.
Consolidated Balance Sheets

September 30,
2024		December 31,
2023
(in thousands, except share and per share amounts)(unaudited)
ASSETS
Current assets:
Cash and cash equivalents$12,595 $19,170 
Marketable securities, short-term— 3,233 
Restricted cash, short-term— 7,030 
Accounts receivable9,970 11,353 
Inventory4,191 4,278 
Prepaid expenses and other current assets403 678 
Current assets of discontinued operations (Note 3)— 510 
Total current assets27,159 46,252 
Property and equipment, net736 825 
Right-of-use assets, net2,647 3,189 
Other assets94 94 
Non-current assets of discontinued operations (Note 3)1,531 3,600 
Total assets$32,167 $53,960 
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable1,711 2,761 
Accrued liabilities1,702 2,887 
Operating lease liabilities, short-term897 718 
Long-term debt, current portion7,084 1,864 
Warrant liability302 409 
Current liabilities of discontinued operations (Note 3)2,969 10,303 
Total current liabilities14,665 18,942 
Operating lease liabilities, long-term2,532 3,243 
Long-term debt25,269 32,654 
Total liabilities42,466 54,839 
Commitments and contingencies (Note 11)
Stockholders' deficit
Preferred stock, $0.001 par value; 5,000,000 shares authorized as of September 30, 2024 and December 31, 2023; 6,666 shares of preferred stock, designated as Series A Common Equivalent Preferred Stock, are issued and outstanding as of September 30, 2024 and December 31, 2023
— — 
Common stock, $0.001 par value; 260,000,000 shares authorized as of September 30, 2024 and December 31, 2023; 29,912,305 and 29,313,667 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively
30 29 
Additional paid-in capital598,670 599,935 
Accumulated deficit(608,118)(599,977)
Accumulated other comprehensive loss(881)(866)
Total stockholders' deficit(10,299)(879)
Total liabilities and stockholders' deficit$32,167 $53,960 


    
image_1.jpg
Acutus Medical, Inc.
Consolidated Statements of Operations and Comprehensive Loss
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
(in thousands, except share and per share amounts)(unaudited)
Revenue$5,266 $2,060 $13,027 $4,816 
Cost of products sold4,894 3,150 13,0197,835
Gross profit (loss)372 (1,090)8 (3,019)
Operating expenses (income):
Research and development— 896 — 2,752 
Selling, general and administrative2,318 2,354 7,880 9,502 
Change in fair value of contingent consideration— — — 123 
Gain on sale of business(2,435)(2,648)(8,096)(5,927)
Total operating expenses (income)(117)602 (216)6,450 
Gain (loss) from operations489 (1,692)224 (9,469)
Other income (expense):
Change in fair value of warrant liability(174)636 107 1,478 
Interest income153 547 641 2,223 
Interest expense(1,395)(1,409)(4,384)(4,110)
    Other revenue111 — 187 — 
Total other expense, net(1,305)(226)(3,449)(409)
Loss from continuing operations before income taxes(816)(1,918)(3,225)(9,878)
Net loss from continuing operations(816)(1,918)(3,225)(9,878)
Discontinued operations:
Loss from discontinued operations before taxes(4,791)(11,244)(4,906)(37,945)
Income tax expense - discontinued operations— 75 10 75 
Net loss from discontinued operations(4,791)(11,319)(4,916)(38,020)
Net loss$(5,607)$(13,237)$(8,141)$(47,898)
Other comprehensive loss
Unrealized loss (gain) on marketable securities— 4 — 7 
Foreign currency translation adjustment(15)(66)(15)(91)
Comprehensive loss$(5,622)$(13,299)$(8,156)$(47,982)
Net loss per share, basic and diluted:
Loss from continuing operations$(0.03)$(0.07)$(0.11)$(0.34)
Loss from discontinued operations$(0.16)$(0.39)$(0.17)$(1.31)
Net loss per common share$(0.19)$(0.45)$(0.27)$(1.65)
Weighted average shares outstanding, basic and diluted29,799,24129,262,76829,768,20829,024,353


    
image_1.jpg
Acutus Medical, Inc.
Consolidated Statements of Cash Flows
Nine Months Ended September 30,
20242023
(in thousands)(unaudited)
Cash flows from operating activities
Net loss$(8,141)$(47,898)
      Less: Loss from discontinued operations4,916 38,020 
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense235 384 
Non-cash stock-based compensation expense459 1,272 
Accretion of discounts on marketable securities, net(28)(1,318)
Amortization of debt issuance costs460 325 
Amortization of operating lease right-of-use assets542 513 
Gain on sale of business, net(8,096)(5,927)
Change in fair value of warrant liability(107)(1,478)
Loss on disposal of property and equipment— — 
Change in fair value of contingent consideration— 123 
Changes in operating assets and liabilities:
Accounts receivable(3,499)3,247 
Inventory87 11,567 
Employer retention credit receivable— 4,703 
Prepaid expenses and other current assets286 2,010 
Accounts payable(1,050)(3,020)
Accrued liabilities(1,442)(8,043)
Operating lease liabilities(532)(253)
Other long-term liabilities— 20 
Net cash used in operating activities - continuing operations(15,910)(5,753)
Net cash used in operating activities - discontinued operations(11,692)(39,352)
Net cash used in operating activities(27,602)(45,105)
Cash flows from investing activities
Proceeds from sale of business13,235 17,000 
Purchases of available-for-sale marketable securities— (38,521)
Sales of available-for-sale marketable securities500 — 
Maturities of available-for-sale marketable securities2,750 70,250 
Purchases of property and equipment(148)(1,187)
Net cash provided by investing activities - continuing operations16,337 47,542 
Net cash provided by (used in) investing activities - discontinued operations339 (207)
Net cash provided by investing activities16,676 47,335 
Cash flows from financing activities
Repayment of debt(2,625)— 
Proceeds from the exercise of stock options— 4 
Repurchase of common shares to pay employee withholding taxes— (35)
Proceeds from employee stock purchase plan— 25 
Net cash (used in) provided by financing activities - continuing operations(2,625)(1,929)
Net cash used in financing activities - discontinued operations(41)(240)
Net cash used in financing activities(2,666)(2,169)
Effect of exchange rate changes on cash, cash equivalents and restricted cash(13)(294)
Net change in cash, cash equivalents and restricted cash(13,605)(233)
Cash, cash equivalents and restricted cash, at the beginning of the period26,200 31,348 
Cash, cash equivalents and restricted cash, at the end of the period$12,595 $31,115 
Supplemental disclosure of cash flow information:
Cash paid for interest3,394 3,731 

    
image_1.jpg
Supplemental disclosure of noncash investing and financing activities:
Accounts receivable from sale of business$4,478 $6,111 
Change in unrealized (gain) on marketable securities$— $(7)
Change in unpaid purchases of property and equipment$— $35 



    
v3.24.3
Cover
Nov. 14, 2024
Cover [Abstract]  
Document Type 8-K
Document Period End Date Nov. 14, 2024
Entity Registrant Name Acutus Medical, Inc.
Entity Incorporation, State or Country Code DE
Entity File Number 001-39430
Entity Tax Identification Number 45-1306615
Entity Address, State or Province CA
Entity Address, City or Town Carlsbad
Entity Address, Address Line Two Suite 100
Entity Address, Address Line One 2210 Faraday Ave.
Entity Address, Postal Zip Code 92008
Local Phone Number 232-6080
City Area Code 442
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001
Trading Symbol AFIB
Entity Emerging Growth Company true
Entity Ex Transition Period false
Entity Central Index Key 0001522860
Amendment Flag false
Acutus Medical (PK) (USOTC:AFIB)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Acutus Medical (PK) Charts.
Acutus Medical (PK) (USOTC:AFIB)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Acutus Medical (PK) Charts.